chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Blood pressure measurement, Confusional state, Feeling abnormal, Inappropriate schedule of product administration
Clinical narrative: felt close to pass out; extreme weak; confusion; loopier; second dose of the Moderna Covid-19 vaccine after recommended dosing interval; This spontaneous case was reported by a consumer and describes the occurrence of PRESYNCOPE (felt close to pass out), ASTHENIA (extreme weak), CONFUSIONAL STATE (confusion), FEELING ABNORMAL (loopier) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose of the Moderna Covid-19 vaccine after recommended dosing interval) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 023C21A and 078C21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concurrent medical conditions included Blood pressure high. Concomitant products included CAPTOPRIL, HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE + CAPTOPRIL) and ATENOLOL for an unknown indication.   On 22-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Jul-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 22-May-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose of the Moderna Covid-19 vaccine after recommended dosing interval). On an unknown date, the patient experienced PRESYNCOPE (felt close to pass out), ASTHENIA (extreme weak), CONFUSIONAL STATE (confusion) and FEELING ABNORMAL (loopier). On 13-Jul-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose of the Moderna Covid-19 vaccine after recommended dosing interval) had resolved. At the time of the report, PRESYNCOPE (felt close to pass out), ASTHENIA (extreme weak), CONFUSIONAL STATE (confusion) and FEELING ABNORMAL (loopier) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 13-Jul-2021, Blood pressure measurement: other (Low) 67/51 low. and other (Low) after salt intake- 74/51 mm Hg..     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) and mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient took some salt to treat the symptoms  No treatment medications were reported   Most recent FOLLOW-UP information incorporated above includes: On 13-Jul-2021: Non-Significant FU (Attached updated snapshot)
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Presyncope
Clinical narrative: felt close to pass out; extreme weak; confusion; loopier; second dose of the Moderna Covid-19 vaccine after recommended dosing interval; This spontaneous case was reported by a consumer and describes the occurrence of PRESYNCOPE (felt close to pass out), ASTHENIA (extreme weak), CONFUSIONAL STATE (confusion), FEELING ABNORMAL (loopier) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose of the Moderna Covid-19 vaccine after recommended dosing interval) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 023C21A and 078C21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concurrent medical conditions included Blood pressure high. Concomitant products included CAPTOPRIL, HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE + CAPTOPRIL) and ATENOLOL for an unknown indication.   On 22-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Jul-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 22-May-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose of the Moderna Covid-19 vaccine after recommended dosing interval). On an unknown date, the patient experienced PRESYNCOPE (felt close to pass out), ASTHENIA (extreme weak), CONFUSIONAL STATE (confusion) and FEELING ABNORMAL (loopier). On 13-Jul-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose of the Moderna Covid-19 vaccine after recommended dosing interval) had resolved. At the time of the report, PRESYNCOPE (felt close to pass out), ASTHENIA (extreme weak), CONFUSIONAL STATE (confusion) and FEELING ABNORMAL (loopier) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 13-Jul-2021, Blood pressure measurement: other (Low) 67/51 low. and other (Low) after salt intake- 74/51 mm Hg..     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) and mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient took some salt to treat the symptoms  No treatment medications were reported   Most recent FOLLOW-UP information incorporated above includes: On 13-Jul-2021: Non-Significant FU (Attached updated snapshot)
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Extra dose administered, Interchange of vaccine products
Clinical narrative: third dose of Moderna COVID19 Vaccine; received the Johnson & Johnson vaccine on 28-May-2021; This spontaneous case was reported by an other health care professional and describes the occurrence of EXTRA DOSE ADMINISTERED (third dose of Moderna COVID19 Vaccine) and INTERCHANGE OF VACCINE PRODUCTS (received the Johnson & Johnson vaccine on 28-May-2021) in an 81-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 28-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 13-Jul-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 28-May-2021, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (received the Johnson & Johnson vaccine on 28-May-2021). On 13-Jul-2021, the patient experienced EXTRA DOSE ADMINISTERED (third dose of Moderna COVID19 Vaccine). On 28-May-2021, INTERCHANGE OF VACCINE PRODUCTS (received the Johnson & Johnson vaccine on 28-May-2021) had resolved. On 13-Jul-2021, EXTRA DOSE ADMINISTERED (third dose of Moderna COVID19 Vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient also received the Johnson & Johnson vaccine on 28-May-2021  No concomitant medications information was reported. No treatment medications were provided.
Sex: M
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: missed the appointment on 19Jun2021 for the 2nd dose of the Moderna vaccine; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (missed the appointment on 19Jun2021 for the 2nd dose of the Moderna vaccine) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.     On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Jun-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (missed the appointment on 19Jun2021 for the 2nd dose of the Moderna vaccine). On 19-Jun-2021, PRODUCT DOSE OMISSION ISSUE (missed the appointment on 19Jun2021 for the 2nd dose of the Moderna vaccine) had resolved.            No concomitant medications information was reported. No treatment medications were provided.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Therapeutic response unexpected
Clinical narrative: Warts on  hands disappeared\ Good Side Effects; This spontaneous case was reported by a consumer and describes the occurrence of THERAPEUTIC RESPONSE UNEXPECTED (Warts on  hands disappeared\ Good Side Effects) in a 23-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. UNK and UNK) for COVID-19 vaccination.     The patient's past medical history included Warts.   In February 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In March 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In February 2021, the patient experienced THERAPEUTIC RESPONSE UNEXPECTED (Warts on  hands disappeared\ Good Side Effects). In March 2021, THERAPEUTIC RESPONSE UNEXPECTED (Warts on  hands disappeared\ Good Side Effects) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment details were reported.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 050C21A and 016C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 28-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Sore arm). At the time of the report, PAIN IN EXTREMITY (Sore arm) outcome was unknown.            No concomitant medications were reported by the reporter. No treatment medications were reported by the reporter. Action taken with mRNA-1273 Moderna COVID-19 Vaccine was not applicable   This case was linked to MOD-2021-255876 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 04-Aug-2021: Follow up received and does not contain any new information.
Sex: M
Vaccine: COVID19
Symptoms: Pain
Clinical narrative: Other people said they felt pain after their first shot.; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Other people said they felt pain after their first shot.) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN (Other people said they felt pain after their first shot.). At the time of the report, PAIN (Other people said they felt pain after their first shot.) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       The concomitant medications were not reported.  The treatment information was not provided.
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Mobility decreased, Muscular weakness, Pain in extremity
Clinical narrative: Some numbness to her right leg; Can't extend toes/feels as if her toes are contracted; Leg felt weak/ feels like she is moving her toes through wet cement; Sore arm; This spontaneous case was reported by a consumer and describes the occurrence of HYPOAESTHESIA (Some numbness to her right leg), MOBILITY DECREASED (Can't extend toes/feels as if her toes are contracted), MUSCULAR WEAKNESS (Leg felt weak/ feels like she is moving her toes through wet cement) and PAIN IN EXTREMITY (Sore arm) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 016C21A and 050C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 28-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced HYPOAESTHESIA (Some numbness to her right leg), MOBILITY DECREASED (Can't extend toes/feels as if her toes are contracted), MUSCULAR WEAKNESS (Leg felt weak/ feels like she is moving her toes through wet cement) and PAIN IN EXTREMITY (Sore arm). At the time of the report, HYPOAESTHESIA (Some numbness to her right leg), MOBILITY DECREASED (Can't extend toes/feels as if her toes are contracted) and MUSCULAR WEAKNESS (Leg felt weak/ feels like she is moving her toes through wet cement) outcome was unknown and PAIN IN EXTREMITY (Sore arm) had resolved.            No concomitant medications were provided. Treatment included Acupressure and Herbal supplements.   This case was linked to MOD-2021-255869 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 04-Aug-2021: Follow-up received contains No new information.
Age: 14.0
Sex: F
Vaccine: COVID19
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: Received first dose underage; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Received first dose underage) in a 14-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Jun-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Received first dose underage). On 18-Jun-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Received first dose underage) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications information was reported.  No treatment medications were provided.   Most recent FOLLOW-UP information incorporated above includes: On 29-Jul-2021: Follow up received contained: An update for a possible change in patient initial (Needs confirmation)
Age: 12.0
Sex: M
Vaccine: COVID19
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: Received first dose under the age of 18; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Received first dose under the age of 18) in a 12-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Jun-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Received first dose under the age of 18). On 02-Jun-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Received first dose under the age of 18) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were provided by the reporter.   Treatment information was not provided.
Sex: U
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: 2 to 3 patients received 2nd dose outside of the recommended 4 week window; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2 to 3 patients received 2nd dose outside of the recommended 4 week window) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2 to 3 patients received 2nd dose outside of the recommended 4 week window). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2 to 3 patients received 2nd dose outside of the recommended 4 week window) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications information was reported. No treatment medications were provided.
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Balance disorder, Diplopia, Fatigue
Clinical narrative: Balance issues; Fatigue; Double vision/2nd vaccine in May, it got worse for a few days then came back to the same as before/he neuro - ophthalmic doctor put a prism on his glasses so he can drive; This spontaneous case was reported by a physician and describes the occurrence of DIPLOPIA (Double vision/2nd vaccine in May, it got worse for a few days then came back to the same as before/he neuro - ophthalmic doctor put a prism on his glasses so he can drive), BALANCE DISORDER (Balance issues ) and FATIGUE (Fatigue) in a 78-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Tetanus and Yellow fever. Concurrent medical conditions included Hypertension and Melanoma. Concomitant products included METOPROLOL, CLOPIDOGREL BISULFATE (PLAVIX), HYDROCHLOROTHIAZIDE and AMLODIPINE for an unknown indication.   On 08-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In May 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 09-May-2021, the patient experienced DIPLOPIA (Double vision/2nd vaccine in May, it got worse for a few days then came back to the same as before/he neuro - ophthalmic doctor put a prism on his glasses so he can drive). On an unknown date, the patient experienced BALANCE DISORDER (Balance issues ) and FATIGUE (Fatigue). At the time of the report, DIPLOPIA (Double vision/2nd vaccine in May, it got worse for a few days then came back to the same as before/he neuro - ophthalmic doctor put a prism on his glasses so he can drive) had not resolved and BALANCE DISORDER (Balance issues ) and FATIGUE (Fatigue) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.    The chronic conditions of the patient were reported as Heart and Prostate and was reported not specifically.  It was reported that patient developed diplopia on 09-MAY-2021 and went to emergency. On 12-MAY-2021patient consulted doctor. The first observation of the reaction event Diplopia was mentioned as 9 eso with half BUOS on 13-MAY-2021 and 20 eso with 3 BUOS on 03-JUN-2021 as stated by the reporter. The reporter stated that the events were continuing from first dose. The treatment for the event was mentioned as Fresnel prism in spectacles. The reporter also stated that third degree  base up had reduced but the horizontal (esotropia)had remained.     This case was linked to MOD-2021-132975 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 14-Jul-2021: The Follow-up document wasreceived contains significant information. The primary reporter details were added. The relevant patient medical history was added. The concomitant products were added. The event outcome for diplopia was updated from unknown to not recovered/not resolved.
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain, COVID-19, Diarrhoea, Nausea, Retching
Clinical narrative: Retching; loose stools; extreme/screaming back pain; nausea; vomiting; This spontaneous case was reported by a consumer and describes the occurrence of RETCHING (Retching), DIARRHOEA (loose stools), BACK PAIN (extreme/screaming back pain), NAUSEA (nausea) and VOMITING (vomiting) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013A21A and 007M20A) for COVID-19 vaccination.     The patient's past medical history included Surgery (scheduled for another spine surgery and fusion on 07-July-2021). Concurrent medical conditions included Penicillin allergy, Drug allergy (codeine(nausea)), Drug allergy (Albuterol (jittery)) and Back pain (caused by spondylolethesis, stenosis, cysts and herniated discs)). Concomitant products included VITAMIN D3 and CALCIUM for Back surgery, ABALOPARATIDE (TYMLOS) from 01-Sep-2020 to an unknown date for Bone development disorder, IBUPROFEN for Pain, OMEPRAZOLE for Reflux gastritis.   On 03-Feb-2021 at 8:30 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Mar-2021 at 8:30 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 04-Mar-2021, the patient experienced RETCHING (Retching), DIARRHOEA (loose stools), NAUSEA (nausea) and VOMITING (vomiting). 04-Mar-2021, the patient experienced BACK PAIN (extreme/screaming back pain). On 08-Mar-2021, RETCHING (Retching), DIARRHOEA (loose stools), BACK PAIN (extreme/screaming back pain), NAUSEA (nausea) and VOMITING (vomiting) had resolved. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In November 2020, COVID-19: positive (Positive) Positive.         No treatment products reported   This case was linked to MOD-2021-034411 (Patient Link).
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: Retching; loose stools; extreme/screaming back pain; nausea; vomiting; This spontaneous case was reported by a consumer and describes the occurrence of RETCHING (Retching), DIARRHOEA (loose stools), BACK PAIN (extreme/screaming back pain), NAUSEA (nausea) and VOMITING (vomiting) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013A21A and 007M20A) for COVID-19 vaccination.     The patient's past medical history included Surgery (scheduled for another spine surgery and fusion on 07-July-2021). Concurrent medical conditions included Penicillin allergy, Drug allergy (codeine(nausea)), Drug allergy (Albuterol (jittery)) and Back pain (caused by spondylolethesis, stenosis, cysts and herniated discs)). Concomitant products included VITAMIN D3 and CALCIUM for Back surgery, ABALOPARATIDE (TYMLOS) from 01-Sep-2020 to an unknown date for Bone development disorder, IBUPROFEN for Pain, OMEPRAZOLE for Reflux gastritis.   On 03-Feb-2021 at 8:30 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Mar-2021 at 8:30 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 04-Mar-2021, the patient experienced RETCHING (Retching), DIARRHOEA (loose stools), NAUSEA (nausea) and VOMITING (vomiting). 04-Mar-2021, the patient experienced BACK PAIN (extreme/screaming back pain). On 08-Mar-2021, RETCHING (Retching), DIARRHOEA (loose stools), BACK PAIN (extreme/screaming back pain), NAUSEA (nausea) and VOMITING (vomiting) had resolved. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In November 2020, COVID-19: positive (Positive) Positive.         No treatment products reported   This case was linked to MOD-2021-034411 (Patient Link).
Age: 25.0
Sex: M
Vaccine: COVID19
Symptoms: Chest discomfort, Dizziness, Heart rate
Clinical narrative: Pinching in the Chest; Light-headed/Dizzy; This spontaneous case was reported by a consumer and describes the occurrence of CHEST DISCOMFORT (Pinching in the Chest) and DIZZINESS (Light-headed/Dizzy) in a 25-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022B21A) for COVID-19 vaccination.     The patient's past medical history included Nerve damage (had nerve damage  when tooth work was being done about 1 year ago.) and Tooth repair (tooth work was being done about 1 year ago).    On 05-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Jul-2021, the patient experienced CHEST DISCOMFORT (Pinching in the Chest) and DIZZINESS (Light-headed/Dizzy). At the time of the report, CHEST DISCOMFORT (Pinching in the Chest) and DIZZINESS (Light-headed/Dizzy) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 09-Jul-2021, Heart rate (65-70): 95-100 (High) 95 -100 BPM.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient advised feels like he may have anxiety, but has not been diagnosed. Patient advised symptoms started while he was doing cardio work.   The concomitant medications used were not reported. Treatment medication were not reported.
Sex: F
Vaccine: COVID19
Symptoms: Inflammation
Clinical narrative: Inflammation; This spontaneous case was reported by a patient and describes the occurrence of INFLAMMATION (Inflammation) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, the patient experienced INFLAMMATION (Inflammation). At the time of the report, INFLAMMATION (Inflammation) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       Treatment for the events include steroid.
Sex: U
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Fever; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PYREXIA (Fever). At the time of the report, PYREXIA (Fever) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications information was reported. No treatment medications were provided.
Sex: M
Vaccine: COVID19
Symptoms: Choking sensation, Cough
Clinical narrative: Lingering Cough; Choking in the middle of the night; This spontaneous case was reported by a patient and describes the occurrence of COUGH (Lingering Cough) and CHOKING SENSATION (Choking in the middle of the night) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   In May 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced COUGH (Lingering Cough). an unknown date, the patient experienced CHOKING SENSATION (Choking in the middle of the night). At the time of the report, COUGH (Lingering Cough) and CHOKING SENSATION (Choking in the middle of the night) outcome was unknown.            The 2nd shot was either on May 2nd or 9th, patient could not remember Patient slept with a CPAP machine (Continuous Positive Airway Pressure Therapy) No concomitant medications information was reported. No treatment medications were provided.
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, Pyrexia
Clinical narrative: few days out from the recommended six week guidelines; fever; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (few days out from the recommended six week guidelines) and PYREXIA (fever) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 15-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (few days out from the recommended six week guidelines) and PYREXIA (fever). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (few days out from the recommended six week guidelines) outcome was unknown and PYREXIA (fever) had resolved.            No concomitant medications were provided. No treatment medications were provided.   This case was linked to MOD-2021-132191 (Patient Link).
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Dyspnoea, Inappropriate schedule of product administration
Clinical narrative: Shortness of breath; Patient received the second dose of the vaccine less than 26 days after the first dose; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (Shortness of breath) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received the second dose of the vaccine less than 26 days after the first dose) in a 22-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 040C21A and 043D21A) for COVID-19 vaccination.     The patient's past medical history included Sickness (before receiving the vaccine).   On 22-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Jul-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 13-Jul-2021, the patient experienced DYSPNOEA (Shortness of breath) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received the second dose of the vaccine less than 26 days after the first dose). On 13-Jul-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received the second dose of the vaccine less than 26 days after the first dose) had resolved. At the time of the report, DYSPNOEA (Shortness of breath) outcome was unknown.            No concomitant medications were provided. No treatment medications were provided.   This case was linked to MOD-2021-255958.
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Hot flush
Clinical narrative: hot flashes; This spontaneous case was reported by a consumer and describes the occurrence of HOT FLUSH (hot flashes) in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038k20a) for COVID-19 vaccination.     No Medical History information was reported.   On 02-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced HOT FLUSH (hot flashes). At the time of the report, HOT FLUSH (hot flashes) outcome was unknown.            No concomitant medications was reported No treatment information was provided   This case was linked to MOD-2021-027162 (Patient Link).
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: got the 2nd vaccine (20May2021) 39 days after the 1st one (11Apr2021); This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (got the 2nd vaccine (20May2021) 39 days after the 1st one (11Apr2021)) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included SERTRALINE HYDROCHLORIDE (ZOLOFT) and BUPROPION HYDROCHLORIDE (WELLBUTRIN) for an unknown indication.   On 11-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (got the 2nd vaccine (20May2021) 39 days after the 1st one (11Apr2021)). The patient was treated with CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]) for Adverse event, at an unspecified dose and frequency; CLARITHROMYCIN (CLARITIN [CLARITHROMYCIN]) for Adverse event, at an unspecified dose and frequency and DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Adverse event, at an unspecified dose and frequency. At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (got the 2nd vaccine (20May2021) 39 days after the 1st one (11Apr2021)) had resolved.            Treatment medications included Steroids   This case was linked to MOD-2021-255602 (Patient Link).
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: Shingles; This spontaneous case was reported by a consumer and describes the occurrence of HERPES ZOSTER (Shingles) in a 67-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 06-Feb-2021, the patient experienced HERPES ZOSTER (Shingles). At the time of the report, HERPES ZOSTER (Shingles) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       Concomitant medications were not provided.  Treatment medications were not provided.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Vaccination site pain, Vaccination site swelling, Vaccination site warmth
Clinical narrative: Injection site is warm to the touch; Sore at the injection site; swelling at injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (Injection site is warm to the touch), VACCINATION SITE PAIN (Sore at the injection site) and VACCINATION SITE SWELLING (swelling at injection site) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 207031A21A and 207030m20A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concurrent medical conditions included Asthma since 1965, Hypothyroidism since 1969, Diabetic since 2000, Acid reflux (esophageal) since 2010, Egg allergy, Penicillin allergy, Sulfonamide allergy, Drug allergy and Hypophosphatasia since 1985.   On 19-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 19-Mar-2021, the patient experienced VACCINATION SITE WARMTH (Injection site is warm to the touch), VACCINATION SITE PAIN (Sore at the injection site) and VACCINATION SITE SWELLING (swelling at injection site). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) 19-Mar-2021 for Swelling, at a dose of 1 dosage form and PARACETAMOL (TYLENOL) at a dose of 1 dosage form. On 31-Mar-2021, VACCINATION SITE WARMTH (Injection site is warm to the touch), VACCINATION SITE PAIN (Sore at the injection site) and VACCINATION SITE SWELLING (swelling at injection site) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 21-Feb-2021, Body temperature: 100.4 f (High) 100.4 F.         The concomitant medications were not reported.  The patient took Benadryl 30 minutes before vaccination and took Tylenol an hour post vaccination. Patient had a medical  history of Flu vaccine
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Illness
Clinical narrative: Felt sick; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (Felt sick) in a 45-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to at an unspecified dose. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On an unknown date, the patient experienced ILLNESS (Felt sick). At the time of the report, ILLNESS (Felt sick) outcome was unknown.            No Concomitant medications were provided  No treatment information was provided   This case was linked to MOD-2021-018537 (Patient Link).   Reporter did not allow further contact
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Malaise, Pain in extremity
Clinical narrative: This spontaneous case reported by a consumer, describes the occurrence of pain in extremity (sore arm) and malaise (didn't feel well) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 vaccine, batch/lot# 030M20A) for COVID-19 immunization. No medical history reported. On Feb 18, 2021, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), intramuscular; 1 dosage form. On an unknown date, patient received the second dose of mRNA-1273 (Moderna COVID-19 vaccine), unknown route; 1 dosage form. On an unknown date, patient experienced pain in extremity (sore arm) and malaise (didn't feel well). At the time of the report, pain in extremity (sore arm) and malaise (didn't feel well): resolved. No concomitant medication or treatment information provided. Patient called in to inquire if she could take ibuprofen after the vaccine. This case linked to MOD-2021-017450 (patient link).
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: fever; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (fever) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PYREXIA (fever). At the time of the report, PYREXIA (fever) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was provided. No treatment medications was provided.   This case was linked to MOD-2021-255983, MOD-2021-023260 (Patient Link).; Sender's Comments: Based on the current available information, a causal relationship cannot be excluded. Further information has been requested regarding vaccination and event dates.
Sex: M
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: Developed a rash on his arms and hands after getting the vaccine; This spontaneous case was reported by a consumer and describes the occurrence of RASH (Developed a rash on his arms and hands after getting the vaccine) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced RASH (Developed a rash on his arms and hands after getting the vaccine). At the time of the report, RASH (Developed a rash on his arms and hands after getting the vaccine) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication details were reported.  It was reported that the patient still had some areas of the rash that have not gone away. No treatment medication details were reported.
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Breath odour, Dizziness, Pain in extremity
Clinical narrative: arm soreness; dizziness; an unusual smell; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (arm soreness), DIZZINESS (dizziness) and BREATH ODOUR (an unusual smell) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012A21A) for COVID-19 vaccination.     Previously administered products included for an unreported indication: FLU VACCINE VII. Concurrent medical conditions included Hypertension. Concomitant products included LOSARTAN for Hypertension, MULTIVITAMINS;MINERALS, VITAMIN B COMPLEX, VITAMIN E [VITAMIN E NOS], ACETYLSALICYLIC ACID (ASPIRIN (E.C.)) and CALCIUM CARBONATE, COLECALCIFEROL (CALTRATE VIT) for Supplementation therapy, LEVOTHYROXINE for Thyroid activity decreased.   On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (arm soreness), DIZZINESS (dizziness) and BREATH ODOUR (an unusual smell). At the time of the report, PAIN IN EXTREMITY (arm soreness), DIZZINESS (dizziness) and BREATH ODOUR (an unusual smell) had resolved.            No treatment information was provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 29-Jul-2021: Follow-up received contains relevant medical history, event and event outcome updated.
Sex: F
Vaccine: COVID19
Symptoms: Headache, Myalgia, Pyrexia
Clinical narrative: fever; headache; body aches; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (fever), HEADACHE (headache) and MYALGIA (body aches) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PYREXIA (fever), HEADACHE (headache) and MYALGIA (body aches). At the time of the report, PYREXIA (fever), HEADACHE (headache) and MYALGIA (body aches) had resolved.            No concomitant medication information provided. No treatment medication information provided.   This case was linked to MOD-2021-019146 (Patient Link).
Sex: F
Vaccine: COVID19
Symptoms: Weight increased
Clinical narrative: Weight gain; This spontaneous case was reported by a consumer and describes the occurrence of WEIGHT INCREASED (Weight gain) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced WEIGHT INCREASED (Weight gain). At the time of the report, WEIGHT INCREASED (Weight gain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Medical history, Lab data, Concomitant medications and Treatment medications are provided.   Most recent FOLLOW-UP information incorporated above includes: On 24-Jul-2021: Follow-up document received on 24-JUL-2021, contains no new information.
Age: 15.0
Sex: F
Vaccine: COVID19
Symptoms: Product administered to patient of inappropriate age, Product dose omission issue
Clinical narrative: Missed dose; A 16 year old patient received the vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (A 16 year old patient received the vaccine) and PRODUCT DOSE OMISSION ISSUE (Missed dose) in a 16-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 26-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-May-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (A 16 year old patient received the vaccine). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Missed dose). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (A 16 year old patient received the vaccine) and PRODUCT DOSE OMISSION ISSUE (Missed dose) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment information was provided.   This case was linked to MOD-2021-268440 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 14-Jul-2021: Follow up contains non significant information. On 25-Jul-2021: Added patient ethnicity, race and second dose information .
Sex: U
Vaccine: COVID19
Symptoms: Myalgia, Pyrexia
Clinical narrative: total body aches; 101.0 fever; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (total body aches) and PYREXIA (101.0 fever) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MYALGIA (total body aches) and PYREXIA (101.0 fever). At the time of the report, MYALGIA (total body aches) and PYREXIA (101.0 fever) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 101.0 (High) 101.0 fever.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant and treatment information were reported by the reporter.
Sex: U
Vaccine: COVID19
Symptoms: Pruritus
Clinical narrative: very bad itching sensation starting in my back and then moving all over my body; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (very bad itching sensation starting in my back and then moving all over my body) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRURITUS (very bad itching sensation starting in my back and then moving all over my body). At the time of the report, PRURITUS (very bad itching sensation starting in my back and then moving all over my body) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Patient received the first dose of the vaccine on 28-Jun-2021. After a day or so patient developed a very bad itching sensation starting in back and then moving all over body